FDA Approves New 10 mg Dosing for Xarelto (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)

TITUSVILLE, NJ, OCTOBER 30, 2017 – Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) approved the 10 mg once-daily dose of Xarelto (rivaroxaban) for reducing the continued risk for recurrent venous...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news